AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in Europe only on a ‘Named Patient’ basis. Trials to obtain full regulatory approval as a biological have progressed well in the EU, but the setback in the US will delay market entry by approximately 12 months. Despite this, AGY remains on course to have the first short-course allergy vaccine approved in both Europe and the US. Despite an operational performance significantly better than all of its competitors, AGY still trades well below the ratings of its international peer group.
26 Sep 2016
Excellent performance drives market share gains
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Excellent performance drives market share gains
Allergy Therapeutics plc (AGY:LON) | 2.8 0 0.0% | Mkt Cap: 135.8m
- Published:
26 Sep 2016 -
Author:
Martin Hall -
Pages:
12
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in Europe only on a ‘Named Patient’ basis. Trials to obtain full regulatory approval as a biological have progressed well in the EU, but the setback in the US will delay market entry by approximately 12 months. Despite this, AGY remains on course to have the first short-course allergy vaccine approved in both Europe and the US. Despite an operational performance significantly better than all of its competitors, AGY still trades well below the ratings of its international peer group.